U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07767864) titled 'Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum' on July 27.
Brief Summary: The purpose of the study is to learn more about an experimental drug bimekizumab that may be helpful for Pyoderma Gangrenosum (PG). Bimekizumab will be referred to as the study drug throughout this form. The investigators are hoping to find out if bimekizumab helps in healing PG wounds. The study drug is experimental. It has been approved by the FDA for use in adults with psoriatic conditions but not for Pyoderma Gangrenosum (PG).
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Pyoderma Gangrenosum
Intervention:
DRUG: Bimek...